ID   S47A1_RAT               Reviewed;         566 AA.
AC   Q5I0E9; Q0KKE7;
DT   04-DEC-2007, integrated into UniProtKB/Swiss-Prot.
DT   15-FEB-2005, sequence version 1.
DT   29-MAY-2024, entry version 125.
DE   RecName: Full=Multidrug and toxin extrusion protein 1;
DE            Short=MATE-1;
DE            Short=rMATE-1;
DE   AltName: Full=Solute carrier family 47 member 1;
GN   Name=Slc47a1; Synonyms=Mate1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, TISSUE
RP   SPECIFICITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Kidney;
RX   PubMed=16928787; DOI=10.1124/dmd.106.010876;
RA   Ohta K.Y., Inoue K., Hayashi Y., Yuasa H.;
RT   "Molecular identification and functional characterization of rat multidrug
RT   and toxin extrusion type transporter 1 as an organic cation/H+ antiporter
RT   in the kidney.";
RL   Drug Metab. Dispos. 34:1868-1874(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], BIOPHYSICOCHEMICAL PROPERTIES, TISSUE
RP   SPECIFICITY, FUNCTION, AND TRANSPORTER ACTIVITY.
RC   TISSUE=Kidney;
RX   PubMed=16850272; DOI=10.1007/s11095-006-9016-3;
RA   Terada T., Masuda S., Asaka J., Tsuda M., Katsura T., Inui K.;
RT   "Molecular cloning, functional characterization and tissue distribution of
RT   rat H+/organic cation antiporter MATE1.";
RL   Pharm. Res. 23:1696-1701(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17047166; DOI=10.1152/ajprenal.00312.2006;
RA   Tsuda M., Terada T., Asaka J., Ueba M., Katsura T., Inui K.;
RT   "Oppositely directed H+ gradient functions as a driving force of rat
RT   H+/organic cation antiporter MATE1.";
RL   Am. J. Physiol. 292:F593-F598(2007).
RN   [5]
RP   FUNCTION.
RX   PubMed=17582384; DOI=10.1016/j.bcp.2007.03.004;
RA   Yokoo S., Yonezawa A., Masuda S., Fukatsu A., Katsura T., Inui K.;
RT   "Differential contribution of organic cation transporters, OCT2 and MATE1,
RT   in platinum agent-induced nephrotoxicity.";
RL   Biochem. Pharmacol. 74:477-487(2007).
RN   [6]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=17296166; DOI=10.1016/j.bcp.2006.12.034;
RA   Nishihara K., Masuda S., Ji L., Katsura T., Inui K.;
RT   "Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in
RT   chronic renal failure rats.";
RL   Biochem. Pharmacol. 73:1482-1490(2007).
RN   [7]
RP   FUNCTION, TRANSPORTER ACTIVITY, MUTAGENESIS OF CYS-62; HIS-64; CYS-95;
RP   HIS-110; CYS-125; CYS-126; CYS-129; HIS-209; HIS-240; CYS-251; CYS-270;
RP   CYS-356; HIS-385; CYS-392; CYS-444; CYS-451; CYS-465; HIS-471 AND HIS-490,
RP   SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17327464; DOI=10.1124/mol.106.032938;
RA   Asaka J., Terada T., Tsuda M., Katsura T., Inui K.;
RT   "Identification of essential histidine and cysteine residues of the
RT   H+/organic cation antiporter multidrug and toxin extrusion (MATE).";
RL   Mol. Pharmacol. 71:1487-1493(2007).
RN   [8]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17616214; DOI=10.1021/mp070023l;
RA   Maeda T., Goto A., Kobayashi D., Tamai I.;
RT   "Transport of organic cations across the blood-testis barrier.";
RL   Mol. Pharm. 4:600-607(2007).
CC   -!- FUNCTION: Multidrug efflux pump that functions as a H(+)/organic cation
CC       antiporter (PubMed:17047166). Plays a physiological role in the
CC       excretion of cationic compounds including endogenous metabolites,
CC       drugs, toxins through the kidney and liver, into urine and bile
CC       respectively (PubMed:16850272, PubMed:16928787, PubMed:17047166,
CC       PubMed:17327464, PubMed:17582384). Mediates the efflux of endogenous
CC       compounds such as creatinine, vitamin B1/thiamine, agmatine and
CC       estrone-3-sulfate (PubMed:16850272, PubMed:16928787, PubMed:17047166,
CC       PubMed:17327464, PubMed:17582384). May also contribute to regulate the
CC       transport of cationic compounds in testis across the blood-testis-
CC       barrier (Probable). {ECO:0000269|PubMed:16850272,
CC       ECO:0000269|PubMed:16928787, ECO:0000269|PubMed:17047166,
CC       ECO:0000269|PubMed:17327464, ECO:0000269|PubMed:17582384,
CC       ECO:0000305|PubMed:17616214}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+)(in) + thiamine(out) = H(+)(out) + thiamine(in);
CC         Xref=Rhea:RHEA:71271, ChEBI:CHEBI:15378, ChEBI:CHEBI:18385;
CC         Evidence={ECO:0000250|UniProtKB:Q96FL8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=estrone 3-sulfate(in) + H(+)(out) = estrone 3-sulfate(out) +
CC         H(+)(in); Xref=Rhea:RHEA:72139, ChEBI:CHEBI:15378, ChEBI:CHEBI:60050;
CC         Evidence={ECO:0000250|UniProtKB:Q96FL8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=creatinine(in) + H(+)(out) = creatinine(out) + H(+)(in);
CC         Xref=Rhea:RHEA:72183, ChEBI:CHEBI:15378, ChEBI:CHEBI:16737;
CC         Evidence={ECO:0000250|UniProtKB:Q96FL8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=agmatine(in) + H(+)(out) = agmatine(out) + H(+)(in);
CC         Xref=Rhea:RHEA:72127, ChEBI:CHEBI:15378, ChEBI:CHEBI:58145;
CC         Evidence={ECO:0000250|UniProtKB:Q96FL8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:72128;
CC         Evidence={ECO:0000250|UniProtKB:Q96FL8};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:72129;
CC         Evidence={ECO:0000250|UniProtKB:Q96FL8};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.260 mM for TEA {ECO:0000269|PubMed:16850272,
CC         ECO:0000269|PubMed:16928787, ECO:0000269|PubMed:17047166,
CC         ECO:0000269|PubMed:17327464};
CC         KM=0.003 mM for cimetidine {ECO:0000269|PubMed:16850272,
CC         ECO:0000269|PubMed:16928787, ECO:0000269|PubMed:17047166,
CC         ECO:0000269|PubMed:17327464};
CC       pH dependence:
CC         Optimum pH is 7.5-8.4. Active from pH 6 to 8.5.
CC         {ECO:0000269|PubMed:16850272, ECO:0000269|PubMed:16928787,
CC         ECO:0000269|PubMed:17047166, ECO:0000269|PubMed:17327464};
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17296166,
CC       ECO:0000269|PubMed:17327464}; Multi-pass membrane protein
CC       {ECO:0000255}. Apical cell membrane {ECO:0000250|UniProtKB:Q96FL8};
CC       Multi-pass membrane protein {ECO:0000255}. Note=Localizes to the plasma
CC       membrane; at the brush border membranes of the proximal tubules
CC       (kidney) and at the bile caniculi (liver).
CC       {ECO:0000250|UniProtKB:Q96FL8}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in kidney and placenta, moderately
CC       in stomach, colon, lung, spleen, skeletal muscle and prostate, and
CC       slightly in spleen. In the kidney, found in medulla and cortex,
CC       especially in the proximal convoluted and straight tubules. No
CC       expression was observed in heart, brain, small intestine and liver.
CC       Expressed in Sertoli cells in testis (PubMed:17616214).
CC       {ECO:0000269|PubMed:16850272, ECO:0000269|PubMed:16928787,
CC       ECO:0000269|PubMed:17296166, ECO:0000269|PubMed:17616214}.
CC   -!- MISCELLANEOUS: Mediates the efflux of cationic compounds such as the
CC       model cations, tetraethylammonium (TEA), the neurotoxin 1-methyl-4-
CC       phenylpyridinium (MPP), the platinum-based drugs cisplatin and
CC       oxaliplatin, the drugs procainamide, acyclovir and topotecan, or weak
CC       bases that are positively charged at physiological pH, such as
CC       cimetidine or the antidiabetic drug metformin.
CC       {ECO:0000269|PubMed:16850272, ECO:0000269|PubMed:16928787,
CC       ECO:0000269|PubMed:17047166, ECO:0000269|PubMed:17327464,
CC       ECO:0000269|PubMed:17582384}.
CC   -!- SIMILARITY: Belongs to the multi antimicrobial extrusion (MATE) (TC
CC       2.A.66.1) family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB248823; BAF02626.1; -; mRNA.
DR   EMBL; AB248824; BAF02627.1; -; mRNA.
DR   EMBL; BC088413; AAH88413.1; -; mRNA.
DR   RefSeq; NP_001014140.1; NM_001014118.2.
DR   AlphaFoldDB; Q5I0E9; -.
DR   SMR; Q5I0E9; -.
DR   STRING; 10116.ENSRNOP00000074897; -.
DR   TCDB; 2.A.66.1.15; the multidrug/oligosaccharidyl-lipid/polysaccharide (mop) flippase superfamily.
DR   PhosphoSitePlus; Q5I0E9; -.
DR   PaxDb; 10116-ENSRNOP00000054704; -.
DR   GeneID; 360539; -.
DR   KEGG; rno:360539; -.
DR   UCSC; RGD:1311123; rat.
DR   AGR; RGD:1311123; -.
DR   CTD; 55244; -.
DR   RGD; 1311123; Slc47a1.
DR   VEuPathDB; HostDB:ENSRNOG00000057404; -.
DR   eggNOG; KOG1347; Eukaryota.
DR   HOGENOM; CLU_012893_1_3_1; -.
DR   InParanoid; Q5I0E9; -.
DR   OrthoDB; 10858at2759; -.
DR   PhylomeDB; Q5I0E9; -.
DR   TreeFam; TF324441; -.
DR   Reactome; R-RNO-425366; Transport of bile salts and organic acids, metal ions and amine compounds.
DR   PRO; PR:Q5I0E9; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000057404; Expressed in adult mammalian kidney and 12 other cell types or tissues.
DR   GO; GO:0016324; C:apical plasma membrane; ISO:RGD.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISO:RGD.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:RGD.
DR   GO; GO:0042887; F:amide transmembrane transporter activity; IDA:RGD.
DR   GO; GO:0015297; F:antiporter activity; ISO:RGD.
DR   GO; GO:0015179; F:L-amino acid transmembrane transporter activity; ISO:RGD.
DR   GO; GO:0061459; F:L-arginine transmembrane transporter activity; ISO:RGD.
DR   GO; GO:0015101; F:organic cation transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0140968; F:polyspecific organic cation:proton antiporter activity; IDA:UniProtKB.
DR   GO; GO:0015489; F:putrescine transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0015234; F:thiamine transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0042910; F:xenobiotic transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0089718; P:amino acid import across plasma membrane; ISO:RGD.
DR   GO; GO:1902475; P:L-alpha-amino acid transmembrane transport; ISO:RGD.
DR   GO; GO:0097638; P:L-arginine import across plasma membrane; ISO:RGD.
DR   GO; GO:0098655; P:monoatomic cation transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006812; P:monoatomic cation transport; IMP:RGD.
DR   GO; GO:0015695; P:organic cation transport; IDA:RGD.
DR   GO; GO:0015847; P:putrescine transport; ISS:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; IDA:RGD.
DR   GO; GO:1990961; P:xenobiotic detoxification by transmembrane export across the plasma membrane; ISO:RGD.
DR   GO; GO:0006855; P:xenobiotic transmembrane transport; ISO:RGD.
DR   GO; GO:0042908; P:xenobiotic transport; ISO:RGD.
DR   CDD; cd13132; MATE_eukaryotic; 1.
DR   InterPro; IPR045069; MATE_euk.
DR   InterPro; IPR002528; MATE_fam.
DR   NCBIfam; TIGR00797; matE; 1.
DR   PANTHER; PTHR11206:SF73; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; 1.
DR   PANTHER; PTHR11206; MULTIDRUG RESISTANCE PROTEIN; 1.
DR   Pfam; PF01554; MatE; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Antiport; Cell membrane; Membrane; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..566
FT                   /note="Multidrug and toxin extrusion protein 1"
FT                   /id="PRO_0000312849"
FT   TRANSMEM        37..57
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        72..92
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        120..140
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        152..172
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        176..196
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        216..236
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        257..276
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        295..315
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        336..356
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        370..390
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        409..429
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        437..457
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        543..563
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96FL8"
FT   MUTAGEN         62
FT                   /note="C->G,F,L,M: Reduction of in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         64
FT                   /note="H->Q: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         95
FT                   /note="C->G: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         110
FT                   /note="H->Q: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         125
FT                   /note="C->G: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         126
FT                   /note="C->G,F,L,M: Reduction of TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         129
FT                   /note="C->G: Modest reduction of TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         209
FT                   /note="H->Q: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         240
FT                   /note="H->Q: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         251
FT                   /note="C->G: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         270
FT                   /note="C->G: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         356
FT                   /note="C->G: Modest reduction of TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         385
FT                   /note="H->Q,F,L,M,P,S,W: Important reduction of TEA
FT                   uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         392
FT                   /note="C->G: Modest reduction of TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         444
FT                   /note="C->G: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         451
FT                   /note="C->G: Modest reduction of TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         465
FT                   /note="C->G: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         471
FT                   /note="H->Q: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   MUTAGEN         490
FT                   /note="H->Q: No change in TEA uptake."
FT                   /evidence="ECO:0000269|PubMed:17327464"
FT   CONFLICT        529
FT                   /note="D -> Y (in Ref. 1; BAF02627)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   566 AA;  61440 MW;  67C9486E9F606A21 CRC64;
     MEVLEEPAPG PGGADAAERR GLRRLLLSGF QEELRALLVL AGPAFLAQLM MFLISFISSV
     FCGHLGKLEL DAVTLAIAVI NVTGISVGHG LSSACDTLIS QTYGSQNLKH VGVILQRGTL
     ILLLCCFPCW ALFINTEQIL LLFRQDPDVS RLTQTYVMVF IPALPAAFLY TLQVKYLLNQ
     GIVLPQVITG IAANLVNALA NYLFLHQLHL GVMGSALANT ISQFALAIFL FLYILWRKLH
     HATWGGWSWE CLQDWASFLQ LAIPSMLMLC IEWWAYEVGS FLSGILGMVE LGAQSITYEL
     AIIVYMIPAG FSVAANVRVG NALGAGNIDQ AKKSSAISLI VTELFAVTFC VLLLGCKDLV
     GYIFTTDWDI VALVAQVVPI YAVSHLFEAL ACTCGGVLRG TGNQKVGAIV NAIGYYVIGL
     PIGISLMFVA KLGVIGLWSG IIICSVCQTS CFLVFIARLN WKLACQQAQV HANLKVNVAL
     NSAVSQEPAH PVGPESHGEI MMTDLEKKDE IQLDQQMNQQ QALPVHPKDS NKLSGKQLAL
     RRGLLFLGVV LVLVGGILVR VYIRTE
//
